Endoscopic Center of Nanjing Chest Hospital, Nanjing, Jiangsu, China.
Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu, China.
J Cell Mol Med. 2019 Mar;23(3):2077-2082. doi: 10.1111/jcmm.14116. Epub 2019 Jan 11.
Pleiotrophin (PTN) is involved in tumour progression, angiogenesis and metastasis. The purpose of this study was to investigate the expression level of PTN in the serum of patients with small cell lung cancer (SCLC) and to explore the clinical significance of PTN. Serum samples from 128 patients with SCLC, 120 healthy volunteers (HV) and 60 patients with benign lung disease (BLD) were collected. The levels of serum PTN were determined with ELISA and its correlation with the clinical data was examined. The serum PTN levels in SCLC patients were significantly higher than that in BLD patients (P < 0.05) or HV (P < 0.05). With a cutoff value of 258.18 ng/mL, the sensitivity and specificity of PTN to SCLC patients and BLD patients, SCLC patients and HV were 79.2% and 91.7%, 86.7% and 95.8% respectively. An area under the curve for all stages of SCLC resulting from PTN, which was significantly better than the other tumour markers tested including progastrin-releasing peptide and neuron-specific enolase. High serum PTN levels appear to correlate with poor survival in patients with SCLC. These results suggest that PTN levels in the serum could be a new effective biomarker for the diagnosis and prognosis of SCLC.
pleiotrophin (ptn) 参与肿瘤的演进、血管生成和转移。本研究旨在探讨小细胞肺癌 (sclc) 患者血清中 ptn 的表达水平及其临床意义。收集了 128 例 sclc 患者、120 例健康志愿者 (hv) 和 60 例良性肺部疾病 (bld) 患者的血清样本。采用酶联免疫吸附试验 (elisa) 测定血清 ptn 水平，并检测其与临床资料的相关性。sclc 患者血清 ptn 水平明显高于 bld 患者 (p < 0.05) 或 hv (p < 0.05)。以 258.18 ng/ml 为截断值，ptn 对 sclc 患者和 bld 患者、sclc 患者和 hv 的灵敏度和特异性分别为 79.2%和 91.7%、86.7%和 95.8%。ptn 对所有分期 sclc 的曲线下面积明显优于其他检测的肿瘤标志物，包括胃泌素释放肽前体和神经元特异性烯醇化酶。高血清 ptn 水平与 sclc 患者的不良预后相关。这些结果表明，血清 ptn 水平可能是 sclc 诊断和预后的一个新的有效生物标志物。
